23 November 2018 in SLEEP
To explore impairments in social functioning in pediatric narcolepsy patients compared to healthy children. Parents of 53 pediatric patients with narcolepsy type 1 and 64 matched healthy children completed the Social Responsiveness Scale (SRS) and the Child Behavior Checklist (CBCL 6–18). Patients scored significantly higher on the total score of the SRS (median 56, IQR 23.5) compared to controls (median 44.5, IQR 8.5, U = 797.0, p<0.001). Patients also scored higher on the sum of the CBCL 6–18 subscales indicative of social functioning (Withdrawn/Depressed, Social Problems and Thought Problems; median 183, IQR 30.5) compared to controls (median 155, IQR 13, U = 500.0, p<0.001). A total of 24 patients (45.3%) reported at least mild to moderate difficulties in social functioning compared to 7 controls (10.9%, χ2 =17.165, p <0.001). Eleven patients (20.8%) and only 1 control (1.6%) had T-scores above 75, which points to severely impaired social functioning (χ2= 11.602, p = 0.001). Within the patient group, girls reported mild to moderate difficulties in social functioning significantly more often compared to boys on the SRS (77.8% versus 28.6%, χ2= 17.560, p < 0.001). Impaired social functioning is common in children with narcolepsy type 1, especially in girls. Questionnaires such as the SRS and the CBCL 6–18 may help in early detection of social problems in pediatric narcolepsy. Recognition of these problems could be valuable in the management of young patients with narcolepsy.
18 June 2025 in Molecular Oncology
Pancreatic cancer has a 5‐year survival rate of 12%, highlighting the need for reliable biomarkers for early detection and disease monitoring. Circulating tumor cells (CTCs) have emerged as a promising biomarker, yet their detection remains challenging. This study evaluates the Parsortix® system, a microfluidic device that enriches CTCs based on size and deformability, using pancreatic cancer cell lines. As increasing evidence indicates that during epithelial‐to‐mesenchymal transition (EMT) a cell's deformability increases, we evaluated possible biases by the device. The EMT stage of three pancreatic cancer cell lines, CAPAN‐1, MIA PaCa‐2, and PANC‐1, was assessed to classify them as epithelial, mesenchymal‐like, and hybrid, respectively. Spike‐in experiments showed that epithelial and hybrid phenotypes were more efficiently captured (62.6 ± 18.5% and 65.4 ± 11.1%) than mesenchymal‐like cancer cells (32.8 ± 10.2%). These results were confirmed using an EMT‐inducible breast cancer cell line. Lower recovery rates were found for the cells in a mesenchymal‐like state (31.5 ± 6.4%) than those in an epithelial state (47.56 ± 7.2%). In conclusion, the Parsortix® device may underestimate the number of mesenchymal CTCs.
7 November 2024 in bioRxiv
Pancreatic cancer has a 5-year survival rate of merely 12%. The high rate of late-stage diagnoses underscores the need for reliable biomarkers for early detection and disease monitoring. Circulating tumor cells (CTCs) have emerged as a promising biomarker, yet their detection remains challenging due to their rarity and phenotypic diversity. This study evaluates the Parsortix® system, a microfluidic device designed to enrich CTCs based on size and deformability, using pancreatic cancer cell lines. As increasing evidence indicates that during epithelial to mesenchymal transition (EMT) a cell’s deformability increases, we evaluated to what extent the Parsortix® system was biased towards epithelial cancer cells. First, the EMT stage of three pancreatic cancer cell lines, CAPAN-1, PANC-1 and MIA PaCa-2, was assessed using immunocytochemistry, flow cytometry and proteomics. CAPAN-1 cells were classified as epithelial, MIA PaCa-2 cells exhibited a mesenchymal-like phenotype, and PANC-1 cells demonstrated a hybrid phenotype. Then, by spiking these cells into blood samples, we determined the Parsortix® system’s ability to recover the cancer cells. Our results indicated that epithelial and hybrid phenotypes are more efficiently captured (62.6 ± 18.5% and 65.4 ± 11.1%) than mesenchymal cancer cells (32.8 ± 10.2%). To confirm these findings, spike-in experiments were repeated using an EMT inducible cell line. Again, significantly lower recovery rates were found for the cells in a mesenchymal-like state (31.5 ± 6.4%) compared to those in an epithelial state (47.56 ± 7.2%). In conclusion, the Parsortix® system may underestimate the presence of mesenchymal CTCs.